Cell line · CVCL_7707
Papers33
1 to 20 of 33
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| SLC15A4 promotes oral cancer progression by regulating TLR9 and activating the JAK/STAT signaling pathway. | Head Face Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genomic Enrichment and Functional Impact of TP53 and CYLD Alterations in Recurrent and Metastatic HPV-Associated Head and Neck Cancer. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting PLK1 Reduces MMP10 to Enhance Radiosensitivity in HPV- Head and Neck Cancer. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer. | Cancer Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Molecular imaging predicts trastuzumab-deruxtecan (T-DXd) response in head and neck cancer xenograft models. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab. | Oncoimmunology | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Effects of Vitamin D on tumor cell proliferation and migration, tumor initiation and anti-tumor immune response in head and neck squamous cell carcinomas. | Biomed Pharmacother | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The Role of TGF-β1 and Mutant SMAD4 on Epithelial-Mesenchymal Transition Features in Head and Neck Squamous Cell Carcinoma Cell Lines. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Dual anti-HER2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC. | Sci Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Differential effect of cancer-associated fibroblast-derived extracellular vesicles on cisplatin resistance in oral squamous cell carcinoma via miR-876-3p. | Theranostics | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Differential Regulation of the STING Pathway in Human Papillomavirus-Positive and -Negative Head and Neck Cancers. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Alterations of lipid-mediated mitophagy result in aging-dependent sensorimotor defects. | Aging Cell | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Fanconi anemia-isogenic head and neck cancer cell line pairs: A basic and translational science resource. | Int J Cancer | 2023 | Cellosaurus cites it, and its Methods give the RRID and name the line | PubMed | |
| p16 Represses DNA Damage Repair via a Novel Ubiquitin-Dependent Signaling Cascade. | Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring. | Cancer Lett | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Necroptosis in head and neck squamous cell carcinoma: characterization of clinicopathological relevance and in vitro cell model. | Cell Death Dis | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Mitochondrial protein import is regulated by p17/PERMIT to mediate lipid metabolism and cellular stress. | Sci Adv | 2019 | Its Methods give the RRID and name the line | PubMed | |
| The genomic landscape of UM-SCC oral cavity squamous cell carcinoma cell lines. | Oral Oncol | 2018 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_7707/papers